Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued ...

Stock analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Insulet in a research note ...

Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...

Bernstein raised the firm’s price target on Insulet (PODD) to $335 from $315 following a strong quarter and an “impressive” outside-U.S.

Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Reports Q4 revenue $597.5M, consensus $582.02M. “We concluded an incredible year with a very strong fourth quarter, achieving significant ...

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Learn more about whether Koninklijke Philips N.V. or Insulet Corporation is a better investment based on AAII's A+ Investor ...

For 2025, Insulet expects revenue growth between 16% and 20%. It projects Omnipod sales to increase by 17%-21%.